The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party

  • Park, Yong (Department of Internal Medicine, Korea University School of Medicine) ;
  • Park, Byung Bae (Department of Internal Medicine, Hanyang University College of Medicine) ;
  • Jeong, Ji Yun (Department of Pathology, Kyungpook National University School of Medicine) ;
  • Kim, Wook Youn (Department of Pathology, Konkuk University Medical Center) ;
  • Jang, Seongsoo (Department of Laboratory Medicine, University of Ulsan College of Medicine) ;
  • Shin, Bong Kyung (Department of Pathology, Korea University School of Medicine) ;
  • Lee, Dong Soon (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Han, Jae Ho (Department of Pathology, Ajou University School of Medicine) ;
  • Park, Chan-Jeoung (Department of Laboratory Medicine, University of Ulsan College of Medicine) ;
  • Suh, Cheolwon (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Insun (Department of Pathology, Korea University School of Medicine) ;
  • Chi, Hyun-Sook (Department of Laboratory Medicine, University of Ulsan College of Medicine)
  • Received : 2015.01.06
  • Accepted : 2016.10.14
  • Published : 2016.11.01
⟨ Previous Next ⟩

Abstract

In September 2011, the Korean Society of Hematology Lymphoma Working Party held a nationwide conference to establish a consensus for assessing bone marrow (BM) involvement in patients with lymphoma. At this conference, many clinicians, hematopathologists, and diagnostic hematologists discussed various topics for a uniform consensus in the evaluation process to determine whether the BM is involved. Now that the discussion has matured sufficiently to be published, we herein describe the consensus reached and limitations in current methods for assessing BM involvement in patients with lymphoma.

Keywords

Acknowledgement

Supported by : Korean Society of Hematology Lymphoma Working Party

References

  1. Zhang QY, Foucar K. Bone marrow involvement by hodgkin and non-hodgkin lymphomas. Hematol Oncol Clin North Am 2009;23:873-902. https://doi.org/10.1016/j.hoc.2009.04.014
  2. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1861.
  3. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636. https://doi.org/10.1200/JCO.1989.7.11.1630
  4. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw 2011;9:1020-1058. https://doi.org/10.6004/jnccn.2011.0086
  5. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010;8:288-334. https://doi.org/10.6004/jnccn.2010.0021
  6. Bayraktar S, Bayraktar UD, Stefanovic A, Lossos IS. Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients. Br J Haematol 2011;152:72-80. https://doi.org/10.1111/j.1365-2141.2010.08429.x
  7. Oh SY, Kim WS, Kim JS, et al. Stage IV marginal zone B-cell lymphoma: prognostic factors and the role of rituximab. Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Sci 2010;101:2443-2447. https://doi.org/10.1111/j.1349-7006.2010.01698.x
  8. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802-806.
  9. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994. https://doi.org/10.1056/NEJM199309303291402
  10. Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013;369:1681-1690. https://doi.org/10.1056/NEJMoa1301077
  11. Yoon JH, Kim JW, Jeon YW, et al. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients. Korean J Intern Med 2015;30:362-371. https://doi.org/10.3904/kjim.2015.30.3.362
  12. Foucar K, Reichard K, Czuchlewski D. Bone Marrow Pathology. 3rd ed. Chicago: American Society for Clinical Pathology Press, 2010.
  13. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057. https://doi.org/10.1056/NEJM199510193331606
  14. Montserrat E, Villamor N, Reverter JC, et al. Bone marrow assessment in B-cell chronic lymphocytic leukaemia: aspirate or biopsy? A comparative study in 258 patients. Br J Haematol 1996;93:111-116. https://doi.org/10.1046/j.1365-2141.1996.449988.x
  15. Jeon YW, Cho SG. Chronic lymphocytic leukemia: a clinical review including Korean cohorts. Korean J Intern Med 2016;31:433-443. https://doi.org/10.3904/kjim.2015.074
  16. Fend F, Kremer M. Diagnosis and classification of malignant lymphoma and related entities in the bone marrow trephine biopsy. Pathobiology 2007;74:133-143. https://doi.org/10.1159/000101712
  17. Foucar K, Reichard K, Wilson C, et al. Diagnostic Pathology: Blood and Bone Marrow. Salt Lake City: Amirsys Pub., 2012.
  18. Brown D, Gatter K, Natkunam Y, Warnke R. Bone Marrow Diagnosis: An Illustrated Guide. Malden: Blackwell, 2006.
  19. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511. https://doi.org/10.1038/35000501
  20. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282. https://doi.org/10.1182/blood-2003-05-1545
  21. Kremer M, Spitzer M, Mandl-Weber S, et al. Discordant bone marrow involvement in diffuse large B-cell lymphoma: comparative molecular analysis reveals a heterogeneous group of disorders. Lab Invest 2003;83:107-114. https://doi.org/10.1097/01.LAB.0000050762.61660.27
  22. Howell SJ, Grey M, Chang J, et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol 2002;119:408-411. https://doi.org/10.1046/j.1365-2141.2002.03842.x
  23. Jeong SY, Chang YH, Lee JK, Hong YJ, Hong SI, Lee SS. Incidence and histologic patterns of bone marrow involvement of malignant lymphoma based on the World Health Organization classification: a single institution study. Korean J Lab Med 2007;27:383-387. https://doi.org/10.3343/kjlm.2007.27.6.383
  24. Bartl R, Frisch B, Burkhardt R, Huhn D, Pappenberger R. Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors. Br J Haematol 1982;51:345-360. https://doi.org/10.1111/j.1365-2141.1982.tb02790.x
  25. Swerdlow SH; International Agency for Research on Cancer; World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer, 2008.
  26. Bene MC, Nebe T, Bettelheim P, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011;25:567-574. https://doi.org/10.1038/leu.2010.312
  27. Kim JM, Park CJ, Jang SS, et al. Clinico-hematologic findings of leukemic bone marrow involvement in Korean patients with non-hodgkin lymphoma. Lab Med Online 2011;1:81-87. https://doi.org/10.3343/lmo.2011.1.2.3
  28. van Dongen JJ, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908-1975. https://doi.org/10.1038/leu.2012.120
  29. The Korean Society of Hematology. Hematology. Seoul: Epublic, 2006.
  30. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. https://doi.org/10.1200/JCO.2006.09.2403
  31. Thiele J, Zirbes TK, Kvasnicka HM, Fischer R. Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma: a practical guideline. J Clin Pathol 1999;52:294-300. https://doi.org/10.1136/jcp.52.4.294
  32. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011;29:1452-1457. https://doi.org/10.1200/JCO.2010.33.3419
  33. Merli M, Arcaini L, Boveri E, et al. Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. Eur J Haematol 2010;85:405-415. https://doi.org/10.1111/j.1600-0609.2010.01503.x
  34. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 2006;76:473-480. https://doi.org/10.1111/j.1600-0609.2006.00644.x
  35. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990;8:1163-1172. https://doi.org/10.1200/JCO.1990.8.7.1163
  36. Morra E, Lazzarino M, Castello A, et al. Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation. Eur J Haematol 1989;42:445-453.
  37. Yan Y, Chan WC, Weisenburger DD, et al. Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol 1995;13:1336-1342. https://doi.org/10.1200/JCO.1995.13.6.1336
  38. Ribrag V, Vanel D, Leboulleux S, et al. Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol 2008;66:325-331. https://doi.org/10.1016/j.ejrad.2007.06.014
  39. Kwee TC, de Klerk JM, Nievelstein RA. Imaging of bone marrow involvement in lymphoma: state of the art and future directions. ScientificWorldJournal 2011;11:391-402. https://doi.org/10.1100/tsw.2011.40
  40. Hanna SL, Fletcher BD, Fairclough DL, Jenkins JH 3rd, Le AH. Magnetic resonance imaging of disseminated bone marrow disease in patients treated for malignancy. Skeletal Radiol 1991;20:79-84.

Cited by

  1. FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma vol.37, pp.2, 2016, https://doi.org/10.1002/hon.2578
  2. Analysis of Overall Survival According to Bone Marrow Aspiration Results in Non-Hodgkin’s Lymphoma Patients vol.94, pp.2, 2016, https://doi.org/10.3904/kjm.2019.94.2.182
  3. First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B-NHL/CLL patients vol.55, pp.4, 2016, https://doi.org/10.5045/br.2020.2020070
  4. Indications and diagnostic value of bone marrow examination in HIV-positive individuals: A 3-year review at Tygerberg Hospital vol.36, pp.1, 2016, https://doi.org/10.4102/sajid.v36i1.273
  5. Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms vol.12, pp.None, 2016, https://doi.org/10.3389/fimmu.2021.784691
  6. Prognostic significance of bone marrow 2-[18F]-fluoro-2-deoxy-D-glucose uptake in diffuse large B-cell lymphoma: relation to iliac crest biopsy results vol.76, pp.7, 2021, https://doi.org/10.1016/j.crad.2021.02.023
  7. FDG PET/CT versus Bone Marrow Biopsy for Diagnosis of Bone Marrow Involvement in Non-Hodgkin Lymphoma: A Systematic Review vol.12, pp.2, 2016, https://doi.org/10.3390/app12020540